Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 4,663 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Therapy Clear all
Withdrawn Not applicable Interventional

Non-Invasive Measurement of Cardiac Output and Stroke Volume in PE

NCT04855370
View directory record Official record
Conditions
Pulmonary Embolism, Pulmonary Embolus/Emboli, Pulmonary Disease, Pulmonary Embolism and Thrombosis, Pulmonary Embolism Subacute Massive, Pulmonary Embolism Acute Massive
Interventions
Non-invasive hemodynamic measurements
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 23, 2026, 10:04 AM EDT
Completed Phase 2 Interventional

Influenza Vaccination in Patients Receiving Antineoplastic Therapy for Non-Hodgkin's Lymphoma

NCT00307710
View directory record Official record
Conditions
Lymphoma
Interventions
Trivalent Baculovirus-expressed Influenza HA vaccine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Oct 23, 2026, 10:04 AM EDT
Recruiting Phase 1 Interventional

Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors

NCT07443020
View directory record Official record
Conditions
Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant, Metastasis to Pleura
Interventions
locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 (IL-2)
Biological · Drug
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 79 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 23, 2026, 10:04 AM EDT
Terminated Phase 4 Interventional Results available

Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure

NCT02053246
View directory record Official record
Conditions
Pulmonary Hypertension, Diastolic Heart Failure, Heart Failure With Preserved Ejection Fraction
Interventions
Nebivolol
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 23, 2026, 10:04 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

NCT00707473
View directory record Official record
Conditions
Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma, Sinonasal Undifferentiated Carcinoma, Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC v8, Stage III Nasal Cavity and Paranasal Sinus Cancer AJCC v8, Stage IVA Nasal Cavity and Paranasal Sinus Cancer AJCC v8, Stage IVB Nasal Cavity and Paranasal Sinus Cancer AJCC v8
Interventions
Carboplatin, Chemoradiotherapy, Cisplatin, Definitive Surgical Resection, Docetaxel, Fluorouracil, Quality-of-Life Assessment, Radiation Therapy
Drug · Other · Procedure + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
17 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 23, 2026, 10:04 AM EDT
Completed Not applicable Interventional

Safety and Effectiveness of Sonu for Pediatric Nasal Congestion

NCT06773013
View directory record Official record
Conditions
Nasal Congestion and Inflammations
Interventions
Acoustic Resonance (Sound) Therapy
Device
Lead sponsor
Third Wave Therapeutics
Industry
Eligibility
12 Years to 21 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Portola Valley, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 23, 2026, 10:04 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

NCT07276724
View directory record Official record
Conditions
Severe Asthma
Interventions
GB-0895, Placebo
Drug
Lead sponsor
Generate Biomedicines
Industry
Eligibility
12 Years to 80 Years
Enrollment
786 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
36
States / cities
Northridge, California • Pasadena, California • Rancho Cucamonga, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma

NCT01122680
View directory record Official record
Conditions
Asthma
Interventions
tiotropium bromide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
5
States / cities
Denver, Colorado • Columbia, Missouri • Warrensburg, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 23, 2026, 10:04 AM EDT
Terminated Phase 3 Interventional

Outpatient Treatment With Anti-Coronavirus Immunoglobulin

NCT04910269
View directory record Official record
Conditions
COVID, SARS-CoV2 Infection, Covid19
Interventions
Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo
Biological · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
16
States / cities
Tucson, Arizona • Mather, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 23, 2026, 10:04 AM EDT
Withdrawn Phase 2 Interventional

Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS

NCT03376854
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Sars-CoV2
Interventions
Hypothermia, Neuromuscular Blocking Agents, Standard of Care
Device · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 23, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19

NCT05164120
View directory record Official record
Conditions
COVID-19
Interventions
Belnacasan, Placebo
Drug
Lead sponsor
MedStar Health
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 23, 2026, 10:04 AM EDT
Recruiting Phase 2 Interventional

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

NCT06116682
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Amivantamab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
Biological · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
271
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Auburn, California + 229 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 23, 2026, 10:04 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma

NCT00435578
View directory record Official record
Conditions
Carcinoma, Small Cell Lung
Interventions
Glufosfamide
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
3
States / cities
Greenbrae, California • Tampa, Florida • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 30, 2009 · Synced Oct 23, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

NCT03526250
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
Interventions
Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
115
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 23, 2026, 10:04 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Nebulized Hypertonic Saline for Bronchiolitis

NCT00619918
View directory record Official record
Conditions
Bronchiolitis
Interventions
Nebulized 3% saline, Nebulized 0.9% saline
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 24 Months
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Los Angeles, California • Oakland, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 23, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC

NCT00130780
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pre-surgical Treatment with Bevacizumab plus Chemotherapy, Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 23, 2026, 10:04 AM EDT
Completed Phase 4 Interventional Results available

Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism

NCT02396758
View directory record Official record
Conditions
Pulmonary Embolism and Thrombosis
Interventions
Ekosonic® Endovascular Device ultrasonic infusion catheter, Recombinant tissue plasminogen activator
Device · Biological
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
16
States / cities
Beverly Hills, California • Tallahassee, Florida • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 23, 2026, 10:04 AM EDT
Terminated Phase 1 Interventional

Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer

NCT00042835
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
cisplatin, etoposide, erlotinib hydrochloride, radiation therapy, docetaxel, paclitaxel, carboplatin, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 23, 2026, 10:04 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Prophylactic Minimally Invasive Surfactant Evaluation

NCT06007547
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn, Premature Birth
Interventions
Poractant Alfa
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
Up to 15 Minutes
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 23, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Statin Therapy in Acute Influenza

NCT02056340
View directory record Official record
Conditions
Influenza
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 23, 2026, 10:04 AM EDT
Completed Not applicable Interventional Results available

Clinical Study for the BONGO Device in the Treatment of Obstructive Sleep Apnea (OSA)

NCT02878590
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
BONGO DEVICE
Device
Lead sponsor
InnoMed Healthscience Inc.
Industry
Eligibility
21 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Alameda, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 23, 2026, 10:04 AM EDT
Completed No phase listed Observational Results available

Utilizing CT Based Imaging Parameters of Body Composition to Understand Heterogeneity of Response to Biologic Therapies in Severe Asthma Cohorts

NCT06922760
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 85 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Denver, Colorado • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 23, 2026, 10:04 AM EDT
Terminated No phase listed Observational

Identifying Novel Aging Targets for Treatment of Delirium

NCT03682874
View directory record Official record
Conditions
Delirium, Dementia Alzheimers, Respiratory Failure
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 23, 2026, 10:04 AM EDT
Terminated Phase 1 Interventional

Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

NCT00937482
View directory record Official record
Conditions
Male Breast Cancer, Stage IV Breast Cancer, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer, Stage IV Renal Cell Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Tumors Metastatic to Brain
Interventions
cediranib maleate, whole-brain radiation therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 23, 2026, 10:04 AM EDT